As global equity markets faltered last week, Advanced Oncotherapy bucked the trend amid chatter of a contract win in China. Speculation Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, secured a second contract in China drove the share price higher last week.
While global equity markets faltered, the Aim-listed company bucked the trend rising by as much 8.8% to 7.5p after chatter emerged its partner for the Chinese market, Sinophi Healthcare, had recently signed a contract with China-Japan Union Hospital of Jilin University, in Changchun, to build a proton therapy centre.
However, the company was quick to dispel rumours it had won another contract for a LIGHT system – its proton beam therapy machine. In a statement, management said “should a purchase order be received, shareholders will be notified”
Full article here